Impax Asset Management Group
BIO icon

Impax Asset Management Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

Impax Asset Management Group’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,845
Closed -$661K – 373
2023
Q3 		$661K Sell
1,845
-34
-2% -$13.1K ﹤0.01% 305
2023
Q2 		$712K Buy
1,879
+800
+74% +$326K ﹤0.01% 304
2023
Q1 		$517K Hold
1,079
– – ﹤0.01% 329
2022
Q4 		$454K Sell
1,079
-43
-4% -$17.4K ﹤0.01% 327
2022
Q3 		$468K Sell
1,122
-46
-4% -$22.9K ﹤0.01% 327
2022
Q2 		$578K Hold
1,168
– – ﹤0.01% 313
2022
Q1 		$658K Sell
1,168
-6
-0.5% -$3.62K ﹤0.01% 323
2021
Q4 		$887K Sell
1,174
-32
-3% -$23.9K ﹤0.01% 299
2021
Q3 		$900K Hold
1,206
– – ﹤0.01% 293
2021
Q2 		$777K Hold
1,206
– – ﹤0.01% 308
2021
Q1 		$689K Buy
+1,206
New +$714K ﹤0.01% 317

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Impax Asset Management Group's BIO Position: Q4 2023 in Review

Impax Asset Management Group sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2023, closing a stake of 1,845 shares — an estimated $661K sold.

Impax Asset Management Group first reported a position in BIO in Q1 2021 and held it in 11 quarters. The position peaked at $900K in Q3 2021. 484 funds tracked by Wall St. Rank hold BIO as of Q4 2023.

  • Impax Asset Management Group reported no remaining Bio-Rad Laboratories Class A position as of Q4 2023 after selling out during the quarter.
  • Impax Asset Management Group sold 1,845 Bio-Rad Laboratories Class A shares in Q4 2023, an estimated $661K.
  • Impax Asset Management Group first reported a position in Bio-Rad Laboratories Class A in Q1 2021 and held it in 11 quarters.
  • Impax Asset Management Group's Bio-Rad Laboratories Class A position peaked at $900K in Q3 2021.
  • 484 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2023.

Based on Impax Asset Management Group's 13F filing for Q4 2023, filed 26 Jan 2024.